Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.58 |
| ▸ | RORC | P51449 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | F10 | P00742 | 3/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13809296 | 1.00 | SLC6A4 (0.58) | SLC6A4RORCSLC6A3SLC6A2F10 | |
| SCHEMBL30693221 | 1.00 | SLC6A4 (0.58) | SLC6A4RORCSLC6A3SLC6A2F10 | |
| SCHEMBL1970755 | 1.00 | SLC6A4 (0.58) | SLC6A4RORCSLC6A3SLC6A2F10 | |
| SCHEMBL7888069 | 0.91 | RORC (0.57) | SLC6A4RORCSLC6A3SLC6A2F10 | |
| SCHEMBL14498495 | 0.91 | RORC (0.57) | SLC6A4RORCSLC6A3SLC6A2F10 | |
| SCHEMBL4661703 | 0.91 | RORC (0.57) | SLC6A4RORCSLC6A3SLC6A2F10 | |
| SCHEMBL4661705 | 0.91 | RORC (0.57) | SLC6A4RORCSLC6A3SLC6A2F10 | |
| SCHEMBL5110560 | 0.91 | RORC (0.57) | SLC6A4RORCSLC6A3SLC6A2F10 | |
| SCHEMBL23951589 | 0.89 | RORC (0.56) | SLC6A4RORCSLC6A3SLC6A2 | |
| SCHEMBL2224784 | 0.89 | RORC (0.56) | SLC6A4RORCSLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656955-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9650334-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| WO-2014140310-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275087-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A7, GFPT1, SUGT1 | SLC6A4 197/4885RORC 4254/4885SLC6A3 190/4885 |
| US-20140275087-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A7, GFPT1, SUGT1 | SLC6A4 197/4885RORC 4254/4885SLC6A3 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.